Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > New JDRF grant will help early career researchers explore fresh ideas in type 1 diabetes
Dr James Pearson, recipient of the first JDRF Small Grant Award, is a type 1 diabetes researcher at Cardiff University
Cardiff University researcher Dr James Pearson is the first recipient of a new JDRF grant designed to test new ideas and expand the horizons of type 1 diabetes research.
Dr Pearson will explore whether the time of day affects the immune system’s ability to regulate itself.
This knowledge could change our understanding of how to discover and test new ways to cure or prevent type 1 diabetes.
Dr Pearson’s project will be funded through the new JDRF UK Small Grant Awards programme, which offers researchers up to £15,000 to test out new concepts that might otherwise go unexplored.
A further two projects funded by the programme are due to begin in October 2021, based at the University of Exeter.
Type 1 diabetes occurs when the immune system mistakenly attacks insulin-producing cells – meaning that its regulatory mechanisms have failed to work as they should.
That is why many researchers are studying how the immune system regulates itself, as a route to discovering treatments that prevent or cure type 1.
However, if the time of day affects how well the immune system can regulate itself, this suggests that a treatment to boost the immune system’s regulation would be more – or less – effective at different times.
Dr Pearson’s work could therefore have significant implications for researchers testing new molecules in the lab for their potential to become new drugs for curing or preventing type 1 diabetes.
It could also affect the way clinical trials of these potential treatments are run, to maximise their chances of success.
The JDRF UK Small Grant Awards programme was set up to fill a hole in the type 1 diabetes funding pipeline.
Currently, to secure funding for large-scale projects, researchers first need early data to build a strong case for financial support.
However, as university budgets have become more constrained, it has become increasingly challenging to obtain the funding to generate this early data. Some funders offer one-year grant schemes to support new ideas, but the application processes also require extensive pilot data – creating a vicious cycle.
The Small Grant Awards programme enables UK-based early career researchers to apply for up to £15,000 for short-term pilot projects. Applications are assessed by the JDRF UK Scientific Advisory Council, with support from external reviewers, and JDRF will be closely monitoring if these awards lead to type 1 researchers securing further grants to develop these ideas.
Rachel Connor, Director of Research Partnerships at JDRF in the UK, said: “For years, researchers have reported to us that it is extremely difficult to get funding for small-scale pilot projects that enable them to explore new ideas and concepts. This means that these fresh ideas can often go unexplored for years.
“We believe that the Small Grant Awards programme will help early career researchers to overcome this challenge, meaning that more great ideas from type 1 diabetes researchers are picked up for further support.”
In a landmark moment, the MHRA has licensed the use of teplizumab in the UK, the first-ever disease-modifying therapy for T1D.
In the study, nearly two thirds of young people diagnosed with type 1 diabetes (T1D) did not have the typical identifiers of the condition.
A recent study has shown that a treatment currently used for type 2 diabetes could be used to help prevent kidney damage in young adults with type 1.
New data from Sana Biotechnology, in collaboration with Uppsala University Hospital in Sweden, shows that six months post-transplant, one person with type 1 diabetes (T1D) is successfully producing insulin and does not require immunosuppression.
